secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2024-08-23T23:59:59+00:00
Accession:  0001493152-24-033753
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Feb 18, 2025
--------------------------------------------------------------------------------

- Received Nasdaq deficiency letter on Aug 22, 2024; bid price below $1.00 for 30 consecutive business days.
- Has until Feb 18, 2025 to regain compliance via closing bid price of $1.00+ for 10 consecutive days.
- May qualify for second 180-day cure period if it meets other listing standards and effects a reverse split.
- TSX listing unaffected; common shares continue trading on Nasdaq under BCTX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224033753/0001493152-24-033753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315224033753/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-033753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer